Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Link
http://www.nature.com/articles/bcj20155.pdf
Reference37 articles.
1. Tefferi A . Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 285–293.
2. Kundranda MN, Tibes R, Mesa RA . Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work? Curr Hematol Malig Rep 2012; 7: 78–86.
3. Cervantes F, Pereira A . Advances in the understanding and management of primary myelofibrosis. Curr Opin Oncol 2011; 23: 665–671.
4. Deisseroth A, Kaminskas E, Grillo J, Chen W, Saber H, Lu HL et al. U.S. Food and drug administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res 2012; 18: 3212–3217.
5. Mascarenhas J, Hoffman R . Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res 2012; 18: 3008–3014.
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The Variation in the Traits Ameliorated by Inhibitors of JAK1/2, TGF-β, P-Selectin, and CXCR1/CXCR2 in the Gata1low Model Suggests That Myelofibrosis Should Be Treated by These Drugs in Combination;International Journal of Molecular Sciences;2024-07-13
2. Programmed Cell Death Deregulation in BCR-ABL1-Negative Myeloproliferative Neoplasms;Programmed Cell Death;2020-01-15
3. Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma;Future Oncology;2019-01
4. GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy;Expert Review of Hematology;2018-02-19
5. Plitidepsin: design, development, and potential place in therapy;Drug Design, Development and Therapy;2017-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3